88790-38-9

Basic information

• Product Name: (S)-1-Boc-2-(2-hydroxyethyl)pyrrolidine
• Synonyms: (S)-1-Boc-2-(2-hydroxyethyl)pyrrolidine;tert-butyl (2S)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate;(S)-tert-Butyl 2-(2-hydroxyethyl)pyrrolidine-1-carboxylate;tert-butyl (S)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate
• CAS NO: 88790-38-9
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.28934
• Mol File: 88790-38-9.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 306.0±15.0 °C(Predicted)
• Appearance: /
• Density: 1.065±0.06 g/cm3(Predicted)
• PKA: 15.03±0.10(Predicted)
• CAS DataBase Reference: (S)-1-Boc-2-(2-hydroxyethyl)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-Boc-2-(2-hydroxyethyl)pyrrolidine(88790-38-9)
• EPA Substance Registry System: (S)-1-Boc-2-(2-hydroxyethyl)pyrrolidine(88790-38-9)

Safety Data

• Hazardous Substances Data: 88790-38-9(Hazardous Substances Data)

Usage

General Description

(S)-1-Boc-2-(2-hydroxyethyl)pyrrolidine, also known as tert-butyl (2S)-1-(2-hydroxyethyl)pyrrolidine-2-carboxylate, is a chemical compound that belongs to the class of pyrrolidine derivatives. It is often used as a reagent in organic synthesis and pharmaceutical research. The compound is a chiral molecule, characterized by its asymmetric carbon center and the presence of a tert-butoxycarbonyl (Boc) protecting group. Due to its versatile reactivity and ability to serve as a building block for the synthesis of various bioactive compounds, (S)-1-Boc-2-(2-hydroxyethyl)pyrrolidine is of great interest in the development of new medicinal agents and potential drug candidates.

Upstream product

• 88790-37-8 (2S)-tert-Butyl 2-(2-methoxy-2-oxoethyl)pyrrolidine-2-carboxylate 
• 56502-01-3 (2S)-1-tert-butoxycarbonyl-2-carboxymethylpyrrolidine 
• 75-21-8 oxirane 
• 86953-79-9 tert-butyl pyrrolidine-1-carboxylate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 84890-94-8 (S)-2-Isobutoxycarbonyloxycarbonyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 141874-26-2 N-Boc-(S)-proline chloride 
• 101130-03-4 tert-butyl (S)-2-(diazoacetyl)pyrrolidine-1-carboxylate 
• 34619-03-9 tert-butyldicarbonate 
• 147-85-3 L-proline 
• 198493-30-0 tert-butyl (2S)-2-(2-oxoethyl)pyrrolidine-1-carboxylate 
• 646062-88-6 (E)-(6-tert-butoxycarbonylamino)-2-hexenal 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 

Downstream Products

• 904680-11-1 methyl 2-({[2-({2-[(2S)-(N-tert-butoxycarbonyl)pyrrolidin-2-yl]ethyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 
• 681247-83-6 methyl 2-({[2-({2-[(2S)-2-pyrrolidinyl]ethyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate 
• 335203-33-3 3-R-7-S-1-aza-3-benzyl-3-methyl-4-thiabicyclo[5.3.0]-2-decanone 
• 335203-32-2 (3S,7S)-1-aza-3-benzyl-3-methyl-4-thiabicyclo[5.3.0]-2-decanone 
• 191528-63-9 [(S)-1-(2-Azido-benzoyl)-pyrrolidin-2-yl]-acetaldehyde 
• 191528-62-8 (2-Azido-phenyl)-[(S)-2-(2-hydroxy-ethyl)-pyrrolidin-1-yl]-methanone 
• 191528-61-7 Carbonic acid 2-[(S)-1-(2-azido-benzoyl)-pyrrolidin-2-yl]-ethyl ester methyl ester 
• 937203-20-8 (S)-N-Boc-2-(bromoethyl)pyrrolidine 
• 1334123-13-5 C₂₃H₃₃FN₂O₃ 
• 933746-73-7 (S)-2-(2-methoxyethyl)pyrrolidine 

Relevant articles and documents

Tetrahydropyrido [3, 4-d] pyrimidine derivative and medical application thereof

The invention relates to a compound as shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate and a preparation method thereof, and application of the compound in preparation of drugs for treating diseases related to KRas-G12C activity or expression quantity.

Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects

Currently used antipsychotics are characterized by multireceptor mode of action. While antagonism of dopamine D2 receptors is responsible for the alleviation of “positive” symptoms of schizophrenia and the effects at other, particularly serotonergic receptors are necessary for their additional therapeutic effects, there is no consensus regarding an “ideal” target engagement. Here, a detailed SAR analysis in a series of 45 novel azinesulfonamides of cyclic amine derivatives, involving the aryl-piperazine/piperidine pharmacophore, central alicyclic amine and azinesulfonamide groups has led to the selection of (S)-4-((2-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)isoquinoline (62). The polypharmacology profile of 62, characterized by partial 5-HT1AR agonism, 5-HT2A/5-HT7/D2/D3R antagonism, and blockade of SERT, reduced the “positive”-like, and “negative”-like symptoms of psychoses. Compound 62 produced no catalepsy, demonstrated a low hyperprolactinemia liability and displayed pro-cognitive effects in the novel object recognition task and attentional set-shifting test. While association of in vitro features with the promising in vivo profile of 62 is still not fully established, its clinical efficacy should be verified in further stages of development.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.